Skip to main content
StemCell Longevita

Respiratory

Who is, and is not, a candidate for MSC therapy in COPD or pulmonary fibrosis?

Written by
StemCell Longevita Editorial Team
Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

Lung indications need spirometry, imaging and an honest conversation about what an infusion can plausibly change.

Medically reviewed by:
Prof. Dr. Erdal Karaöz, PhD
Last reviewed:
Next review:

The short answer

Human MSC trials in COPD and in idiopathic pulmonary fibrosis have mostly tested safety, and they generally report that infusion is tolerated without consistent improvement in lung function. We consider treatment only for stable, moderate disease alongside pulmonary rehabilitation, and we decline where oxygen dependence or transplant assessment makes the risk-benefit unfavourable.

Who this decision applies to

Usually appropriate to discuss

  • Stable moderate disease with spirometry and HRCT from the last twelve months
  • Smoking stopped, and pulmonary rehabilitation under way
  • Comorbid cardiac disease assessed and controlled
  • Understanding that the realistic aim is symptom and quality-of-life support

Not appropriate right now

  • Severe hypoxaemia, high oxygen requirement or recent exacerbation
  • Active infection, including untreated tuberculosis
  • Patients under active transplant assessment, unless their team agrees
  • Continued smoking

Evidence at a glance

The same five questions we ask of every indication, answered for this one.

Evidence maturity for COPD and pulmonary fibrosis candidacy
QuestionAnswerWhat that means here
Human studies published?YesPhase 1/2 human trials in COPD and IPF are published.
Randomised controlled trials?LimitedA small number of randomised, placebo-controlled studies exist.
Objective outcome measures?YesFEV1, DLCO, six-minute walk distance and quality-of-life scores are reported.
Long-term follow-up (≥12 months)?LimitedMost follow-up ends at 12 months.
Approved as a routine therapy?NoNot approved for either indication; antifibrotics remain standard care in IPF.

How these judgements are made: How we evaluate evidence · Editorial standards · Conflict-of-interest disclosure.

Options compared, including doing nothing

Realistic options for COPD and pulmonary fibrosis candidacy
OptionWhat it can realistically doMain trade-off
Pulmonary rehabilitation and inhaled therapyThe best-evidenced symptom and exacerbation control in COPDRequires sustained participation
Antifibrotic therapy in IPFSlows decline in lung functionSide effects; does not reverse fibrosis
MSC therapy as an adjunctSafety reported as acceptable; benefit unprovenCost and travel with no guaranteed change
Transplant assessmentThe only intervention that replaces failing lung tissueStrict criteria and long waiting lists

How the decision is made in practice

  1. We require recent spirometry with DLCO, HRCT and a six-minute walk test where available.
  2. We confirm smoking cessation and rehabilitation participation before considering treatment.
  3. We check exacerbation history; recent hospitalisation defers any decision.
  4. We state the realistic aim — symptom and quality-of-life support — and record baseline measures.
  5. Follow-up repeats the same measures at three, six and twelve months.

When we decline, and why

  • Oxygen-dependent or end-stage disease
  • Ongoing smoking, because it undermines any plausible mechanism
  • Recent exacerbation or active infection
  • Expectation that fibrosis will be reversed

Declining is a normal outcome of assessment, not a failure of it. See how candidacy and redirection work.

Questions worth asking any clinic

  • Which lung-function measures will be recorded, and how do they compare with published trial results?
  • What did the randomised trials in my specific condition report?
  • How is infusion safety managed in patients with pulmonary hypertension?
  • What are the criteria for declining treatment here?

Frequently asked questions

No published human trial has demonstrated reversal of established fibrosis. Trials in IPF have largely reported safety and feasibility, with lung-function decline continuing in most participants. Antifibrotic medication remains the treatment with disease-modifying evidence.

Published randomised data do not show consistent FEV1 improvement in COPD. Where patients report feeling better, quality-of-life scores may change without a matching spirometry change, and we record both so the distinction stays visible.

Continued smoking maintains the inflammatory injury the therapy is meant to modulate, and it makes any assessment of effect meaningless. It is also the single intervention with the largest proven effect on outcome in COPD.

Sources

  1. mesenchymal stem cells COPD clinical trial — MSC trials in chronic obstructive pulmonary disease.
  2. mesenchymal stromal cells idiopathic pulmonary fibrosis trial — MSC studies in idiopathic pulmonary fibrosis.
  3. mesenchymal stromal cells chronic obstructive pulmonary disease — Registered respiratory trials.

Citation practice and source hierarchy: How we evaluate evidence.

Related clinical questions

Want this reviewed for your own case?

Send your diagnosis, imaging and medication list. If the answer is no, we will say so and explain why.

Request a medical review · Check candidacy in 6 questions

How to cite this page

This page's evidence table is published under CC BY 4.0. Reuse it with attribution and a link back.

How to cite this page
StyleCitation
APAStemCell Longevita. (2026). Who is, and is not, a candidate for MSC therapy in COPD or pulmonary fibrosis?. StemCell Longevita. https://stemcelllongevita.com/clinical-decisions/copd-pulmonary-fibrosis-candidacy
VancouverStemCell Longevita. Who is, and is not, a candidate for MSC therapy in COPD or pulmonary fibrosis? [Internet]. Istanbul: StemCell Longevita; 2026 [cited 2026-08-23]. Available from: https://stemcelllongevita.com/clinical-decisions/copd-pulmonary-fibrosis-candidacy

BibTeX:

@techreport{longevita_copd_pulmonary_fibrosis_candidacy_2026,
  title       = {Who is, and is not, a candidate for MSC therapy in COPD or pulmonary fibrosis?},
  author      = {{StemCell Longevita}},
  institution = {StemCell Longevita},
  year        = {2026},
  url         = {https://stemcelllongevita.com/clinical-decisions/copd-pulmonary-fibrosis-candidacy},
  urldate     = {2026-08-23}
}

Structured data: The evidence table on this page is also published as a machine-readable dataset descriptor. /cite

Related pages